News

The interim analysis was conducted after the first 20 patients enrolled into the trial had been treated for at least two months or had discontinued from the trial.

Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s

Earlier, the firm also secured breakthrough therapy status for CTL019 to treat r/r B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. The University of Pennsylvania

The randomized phase 2 clinical trial, dubbed PINNACLE, featured 145 patients. Tarextumab was administered in combination with etoposide plus either cisplatin or carboplatin chemotherapy in patients who were previously untreated for

The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 741 and affects nearly

Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen. ODAC is

According to the company, emicizumab prophylaxis demonstrated a clinically meaningful reduction in the number of bleeds over time at this interim analysis after a median of 12 weeks

Supported by data from five clinical studies involving 660 patients, IBI is seeking FDA marketing approval of Dexycu as a long-acting dropless treatment for inflammation associated with cataract

The company’s novel therapeutic oral delivery platform has the potential to transform patient care by improving therapeutic efficacy, reducing side effects, and generating cost-savings to patients and healthcare